Skip to main content
. 2022 Mar 1;13:848387. doi: 10.3389/fimmu.2022.848387

Figure 2.

Figure 2

Kaplan-Meier analyses of overall survival (A) and progression-free survival (B) according to treatment groups. TACE-L-P, transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor; TACE-L, transarterial chemoembolization combined with lenvatinib.